Research letterGeneralized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series
References (5)
- et al.
Stevens-Johnson syndrome during nivolumab treatment of NSCLC
Ann Oncol
(2018) - et al.
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
J Am Acad Dermatol
(2019)
There are more references available in the full text version of this article.
Cited by (16)
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study
2022, Journal of Investigative DermatologyCitation Excerpt :For SJS (affecting <10% body surface area) and TEN (affecting >30% body surface area), there is no overlap syndrome for body surface area affecting 10‒30% body surface area. There also has been a unique bullous eruptive cirAE mimicking SJS and TEN, however with rapid response to immunosuppression and lower mortality (Molina et al., 2020). Because VigiBase does not have the clinical nuance to identify this morphology, this was unable to be studied.
Immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions
2021, Journal of the American Academy of DermatologyLesions in the oral mucosa associated with the use of checkpoint inhibitors: A bibliometric and critical review
2024, Special Care in DentistryManagement of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis:A Case Report and Literature Review
2023, Journal of Drugs in Dermatology
Funding sources: None.
Conflicts of interest: None disclosed.
IRB approval status: This study was approved by the Partners Human Research Committee, the Institutional Review Board of Partners HealthCare (#2017P000501).
Reprints not available from the authors.
© 2020 by the American Academy of Dermatology, Inc.